Beyond Life Support: FDA Fast-Tracks Novel Drug for Cardiogenic Shock

Hennigsdorf/Berlin, July 16, 2026 – In the high-stakes world of critical care medicine, few diagnoses are as grim as cardiogenic shock. Today, German biotechnology firm 4TEEN4 Pharmaceuticals GmbH announced a significant step forward in combating this lethal condition, receiving Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead drug candidate, invobenitug.

The designation, granted for the treatment of cardiogenic shock, is intended to accelerate the development and review of what could be the first therapy to target the underlying biological cause of the syndrome, rather than just its devastating symptoms. Invobenitug, an investigational monoclonal antibody, is currently being evaluated in a Phase 1b/2a clinical trial.

“Fast Track designation represents an important milestone for 4TEEN4 as we continue to advance invobenitug through clinical development,” said Dr. Andreas Bergmann, CEO of 4TEEN4 Pharmaceuticals. “The designation recognizes both the significant unmet medical need in cardiogenic shock and the potential of invobenitug as a targeted therapeutic approach.”

A New Front Against a Formidable Killer

Cardiogenic shock is a brutal, rapidly escalating crisis where the heart fails to pump enough oxygenated blood to sustain the body’s vital organs. It is the second most common form of circulatory failure and accounts for approximately one in three admissions to intensive care units. Despite decades of advances in supportive care—including powerful drugs to raise blood pressure and mechanical pumps to assist the heart—the mortality rate remains stubbornly high, exceeding 50%.

The core challenge has been a lack of therapies that address the molecular chaos unfolding within the patient. Current treatments are reactive, managing the downstream consequences of circulatory collapse. This regulatory acceleration for invobenitug signals a potential shift towards a proactive, targeted strategy.

“Cardiogenic shock remains one of the most challenging conditions in acute cardiovascular medicine, with mortality rates exceeding 50% and no approved therapies that target the underlying biology,” commented Alexandre Mebazaa, MD, PhD, a Professor of Medicine at Université Paris Cité and the Principal Investigator for the ongoing clinical study. “Rather than simply treating the downstream consequences of shock, our goal is to intervene at its biological root by neutralizing cDPP3 in patients most likely to benefit. This designation marks an important step towards establishing one of the first targeted therapeutic approaches for cardiogenic shock.”

Rewiring the Body's Response: The Science of cDPP3

To understand the innovation behind invobenitug is to understand the role of a rogue enzyme: circulating dipeptidyl peptidase 3 (cDPP3). Under normal conditions, DPP3 is an intracellular enzyme. However, during the massive cellular injury that occurs in cardiogenic shock, DPP3 is released into the bloodstream, where it becomes a key driver of mortality.

Once in circulation, cDPP3 begins to degrade vital signaling molecules, most notably angiotensin II. This peptide is a cornerstone of the renin-angiotensin-aldosterone system (RAAS), the body’s primary mechanism for regulating blood pressure and fluid balance. By destroying angiotensin II, cDPP3 effectively sabotages the body's attempts to stabilize itself, leading to profound hypotension, organ failure, and death.

Invobenitug is a humanized monoclonal antibody designed with a single, precise mission: to find and neutralize cDPP3 in the bloodstream. By inhibiting the enzyme's activity, the antibody is intended to protect angiotensin II from degradation, thereby restoring the function of the RAAS, stabilizing cardiovascular function, and giving the body’s organs a chance to recover. This approach represents a paradigm shift—moving from broadly supporting a failing system to surgically removing a key pathological agent.
The company's biomarker-guided strategy is also a hallmark of modern drug development. The ongoing trial specifically enrolls patients with elevated cDPP3 concentrations, ensuring the drug is tested in the population most likely to respond to its unique mechanism.

The Strategic Advantage of the Fast Lane

For a clinical-stage biotechnology company like 4TEEN4, an FDA Fast Track designation is more than just a procedural boost; it is a significant strategic and financial catalyst. This regulatory validation provides a crucial de-risking signal to investors and potential partners, confirming that the FDA recognizes both the gravity of the unmet medical need and the scientific plausibility of the proposed solution.

The tangible benefits are substantial. The program allows for more frequent meetings and communication with the FDA, enabling the company to align on clinical trial design and data requirements, which can prevent costly delays. More importantly, it opens the door to several mechanisms that can drastically shorten the timeline to market. Invobenitug could become eligible for Rolling Review, where 4TEEN4 can submit sections of its final marketing application as they are completed, rather than waiting for the entire package. Furthermore, it creates a potential pathway to Accelerated Approval, based on surrogate endpoints, and Priority Review, which would shorten the FDA’s review clock from the standard ten months to just six.

This acceleration is critical in a field where time directly translates to lives and market opportunity. By navigating the regulatory process more efficiently, 4TEEN4 can potentially bring its first-in-class therapy to critically ill patients sooner, establishing a strong foothold in a market that has been barren of targeted innovation for decades.

The Gauntlet: Proving Potential in the PROCARD 2a Trial

The promise of invobenitug now rests on the execution and outcome of the PROCARD 2a clinical trial (NCT06832722). The study is a multicenter, randomized, double-blind, placebo-controlled Phase 1b/2a trial—the gold standard for generating unbiased evidence of a drug's safety and efficacy. Its primary purpose is to assess safety, tolerability, and pharmacokinetics, while also exploring early signals of efficacy in patients with cardiogenic shock and elevated cDPP3 levels.

With an estimated primary completion date of April 2027, the trial is actively recruiting patients across multiple sites. The scientific and medical communities will be watching its progress closely. Favorable safety data from a completed Phase 1 study in healthy volunteers provided the foundation for this next crucial step. Now, 4TEEN4 must demonstrate that invobenitug can safely and effectively disrupt the fatal cascade driven by cDPP3 in one of medicine's most vulnerable patient populations.